Discover and read the best of Twitter Threads about #EGFRex20

Most recents (3)

#WCLC20 CHRYSALIS trial results with amivantamab in #EGFRex20 NSCLC post-platinum based chemotherapy presented by @JSabari. Amivantamab has FDA breakthrough designation for this indication. @IASLC #LCSM @OncoAlert
#WCLC20 Amivantamab is an EGFR-MET bispecific antibody given intravenously weekly x 1 month then q2w. This is a single arm phase II for patients with #EGFRex20 mutant NSCLC after prior chemotherapy. #LCSM
#WCLC20 Amivantamab was reasonably well tolerated. G3 TEAE in 35% but treatment-related rate only 16%. Drug related AE leading to discontinuation only 4%. Mostly G1-2 adverse events including rash, paronychia. #LCSM
Read 4 tweets
#WCLC20 Highly anticipated results of oral TKI mobocertinib (TAK-788) in #EGFRex20 mutant NSCLC after prior platinum based chemotherapy. Huge unmet need and as @Jbauml reported at this meeting, likely underdiagnosed. #LCSM @IASLC @OncoAlert
#WCLC20 Cohort being discussed here is #EGFR exon 20 insertion NSCLC after prior platinum therapy and the EXCLAIM extension cohort. Many patients also had prior TKI therapy and prior immunotherapy. @IASLC
#WCLC20 Here are the topline results. RR 23-26% by IRC, RR 32-35% by investigator, DOR by IRC was 17.5m (!) and mPFS 7.3m -- for #EGFRex20, no clear standard. Mobocertinib certainly has some activity here. #LCSM
Read 6 tweets
#OncoAlert #AACR20 Long awaited data from TAK-788 (now mobocertinib) in #EGFR exon 20 #NSCLC - this is clearly an unmet need with poor outcomes achieved using standard EGFR TKIs or immunotherapy. TAK-788 has some promising features to help in this setting #LCSM ImageImage
#OncoAlert #AACR20 Dose escalation of TAK-788 (mobocertinib) established MTD of 160mg qday. DLTs were 1 case each of grade 3 diarrhea, grade 3 mucositis, grade 3 pneumonitis, and grade 5 (fatal) pneumonitis. Study then enrolled into 7 different baskets to explore efficacy. #LCSM ImageImage
#OncoAlert #AACR20 In patients with #EGFRex20 #NSCLC treated with TAK-788 at 160mg, RR was 43% (n=28) including ASV mutations and NPH insertions. mPFS 7.3 months. Responses independent of prior therapy. Certainly encouraging - need more numbers, longer f/u, full dataset. #LCSM Image
Read 5 tweets

Related hashtags

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!